Hong Kong stock market anomaly | Sanlife Pharmaceutical (01530.HK) surged nearly 7% in early trading, Pfizer initiated two global Phase III clinical trials of SSGJ-707.

According to the UMoney APP, Sanzen Pharmaceuticals (01530.HK) rose nearly 7% in the morning session, as of the time of writing, it rose 6.43% to HK$29.46, with a turnover of HK$381 million.